Skip to Content Skip to Search

Our presentations at ASH 2020

DREAMM Analyses

Abstract Name

Presenter

Presentation Details

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes by Prior Therapies

S. Lonial

Poster #1417

 

Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

G. Ferron-Brady

Poster #1420

 

DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

R. Popat

Poster #2278

 

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

A. Nooka

Poster #3221

 

Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

S. Lonial

Poster #3224

 

Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study

L. Eliason

Poster #3248

 

DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With Four Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

P. Richardson

Poster #2299

 

DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

R. Popat

Poster #1419

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

R. Rifkin

Poster #3247

 

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

S. Trudel

Poster #2302

 

Real-World Multiple Myeloma Data

Abstract Name

Presenter

Presentation Details

Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA

G. Kanas

Poster #2300